Alnylam Pharmaceuticals

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R.

CEO

Yvonne L. Greenstreet

CEOYvonne L. Greenstreet

Employees

2,500

Employees2,500

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2002

Founded2002

Employees

2,500

Employees2,500

ALNY Key Statistics

Market cap

30.03B

Market cap30.03B

Price-Earnings ratio

37.79

Price-Earnings ratio37.79

Dividend yield

—

Dividend yield—

Average volume

1.32M

Average volume1.32M

High today

$229.56

High today$229.56

Low today

$222.25

Low today$222.25

Open price

$223.50

Open price$223.50

Volume

1.11M

Volume1.11M

52 Week high

$495.55

52 Week high$495.55

52 Week low

$197.81

52 Week low$197.81

Stock Snapshot

As of today, Alnylam Pharmaceuticals(ALNY) shares are valued at $226.36. The company's market cap stands at 30.03B, with a P/E ratio of 37.79.

On 2026-10-14, Alnylam Pharmaceuticals(ALNY) stock traded between a low of $222.25 and a high of $229.56. Shares are currently priced at $226.36, which is +1.8% above the low and -1.4% below the high.

Alnylam Pharmaceuticals(ALNY) shares are trading with a volume of 1.11M, against a daily average of 1.32M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $197.81.

ALNY News

TipRanks 11h

Alnylam price target lowered to $253 from $256 at Wells Fargo

Wells Fargo analyst Derek Archila lowered the firm’s price target on Alnylam (ALNY) to $253 from $256 and keeps an Equal Weight rating on the shares ahead of qu...

TipRanks 12h

Alnylam price target lowered to $320 from $340 at Citi

Citi lowered the firm’s price target on Alnylam (ALNY) to $320 from $340 and keeps a Buy rating on the shares ahead of the Q3 report. The firm cites reduced lon...

Benzinga 1d

If You Invested $1000 In Alnylam Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today - Benzinga

...

Analyst ratings

72%

of 32 ratings

Buy

71.9%

Hold

28.1%

Sell

More ALNY News

Simply Wall St 3d

How Securities Fraud Scrutiny Will Impact Alnylam Stock Investors

Alnylam Pharmaceuticals faces ongoing securities fraud scrutiny linked to a sharp reduction in sales expectations for its TTR franchise. This has prompted fresh...

Simply Wall St 4d

Alnylam Pharmaceuticals Could Be 37% Undervalued After TTR Sales Probe

Investor focus on Alnylam Pharmaceuticals (ALNY) has sharpened after news of a securities fraud investigation tied to reduced TTR sales expectations, prompting...

Simply Wall St 6d

Alnylam Pharmaceuticals Is Under Securities Fraud Investigation

Alnylam Pharmaceuticals (NasdaqGS:ALNY) faces an ongoing securities fraud investigation following a downward revision to its 2026 sales guidance. Investigators...

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Waystar Holding Corp.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.